Search results for "Viral vector"

showing 10 items of 57 documents

Virotherapy in Germany—Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies

2021

Virotherapy research involves the development, exploration, and application of oncolytic viruses that combine direct killing of cancer cells by viral infection, replication, and spread (oncolysis) with indirect killing by induction of anti-tumor immune responses. Oncolytic viruses can also be engineered to genetically deliver therapeutic proteins for direct or indirect cancer cell killing. In this review—as part of the special edition on “State-of-the-Art Viral Vector Gene Therapy in Germany”—the German community of virotherapists provides an overview of their recent research activities that cover endeavors from screening and engineering viruses as oncolytic cancer therapeutics to their cli…

0301 basic medicinemedicine.medical_treatmentGenetic enhancementvirus targetingMedizinReviewcombination therapychemistry.chemical_compoundDDC 570 / Life sciencesClinical trials0302 clinical medicineKlinisches ExperimentGermanyNeoplasmsMedicineimmunotherapy ; therapeutic transgene ; combination therapy ; Virustherapie ; clinical trials ; virus engineering ; oncolytic virus ; research in Germany ; virus targeting ; virotherapyOncolytic VirotherapyClinical Trials as Topicvirus engineeringKombinationstherapieQR1-5023. Good healthOncolytic VirusesInfectious Diseases030220 oncology & carcinogenesisImmunotherapyvirotherapyGenetic Engineeringresearch in GermanyMicrobiologyVirusViral vector03 medical and health sciencesImmune systemddc:570VirologyAnimalsHumanstherapeutic transgeneVirotherapyoncolytic virusbusiness.industryImmunotherapyVirologyOncolytic virusImmuntherapie030104 developmental biologychemistryVacciniabusinessViruses
researchProduct

SOLID LIPID NANOPARTICLES FOR APPLICATIONS IN GENE THERAPY: A REVIEW OF THE STATE OF THE ART

2010

Importance of the field. Gene therapy represents a new paradigm in the prevention and treatment of many inherited and acquired diseases, including genetic disorders, such as cystic fibrosis, haemophilia and many somatic diseases, such as tumours, neurodegenerative diseases and viral infections, such as AIDS. Areas covered in this review. Among a large array of non-viral transfection agents used for in-vitro applications, cationic SLNs are the topic of this review, being recently proposed as an alternative carrier for DNA delivery, due to many technological advantages such as large-scale production from substances generally recognized as safe, good storage stability and possibility of steam …

Acquired diseasesGenetic enhancementGenetic VectorsPharmaceutical ScienceGene deliveryBiologyBioinformaticsCystic fibrosisGenetic therapyGENE THERAPY SOLID LIPID NANOPARTICLESSolid lipid nanoparticlemedicinegene deliverybusiness.industrynon-viral vectors Read More: http://informahealthcare.com/doi/abs/10.1517/17425240903362410DNAGenetic Therapymedicine.diseasegene therapyLipidsBiotechnologySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoMicroscopy Electron ScanningNanoparticlesbusinesscationic solid lipid nanoparticles
researchProduct

Factors Affecting Hesitancy to mRNA and Viral Vector COVID-19 Vaccines among College Students in Italy

2021

Vaccine hesitancy (VH) may be significant in jeopardizing efforts to mass containment of COVID-19. A cross-sectional survey was carried out on a sample of 2667 Italian college students, before the COVID-19 vaccines became available for this age group (from 7 May to 31 May 2021). An online survey was created to obtain information about socio-demographic, health-related, and psychological factors linked to mRNA and viral vector COVID-19 vaccines. Statistically significant higher VH (30.4%) and vaccine resistance (12.2%) rates were found for viral vector than mRNA COVID-19 vaccines (7.2% and 1.0%, respectively; p < 0.001). Factors related to viral vector VH were partially different from tho…

Agreeablenessmedicine.medical_specialty2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Immunologyvaccine hesitancy; COVID-19; mRNA vaccines; viral vector vaccines; college students; ItalyArticleViral vectorOddsDrug DiscoverymedicinePharmacology (medical)Pharmacologybusiness.industryPublic healthcollege studentsRCOVID-19mRNA vaccinesInfectious DiseasesItalyviral vector vaccinesvaccine hesitancyMedicinebusinessDemographyVaccines
researchProduct

Magnetic resonance imaging of viral particle biodistribution in vivo

2006

We describe here a technique for the visualization of viral vector delivery by magnetic resonance imaging (MRI) in vivo. By conjugating avidin-coated baculoviral vectors (Baavi) with biotinylated ultra-small superparamagnetic iron oxide particles (USPIO), we are able to produce vector-related MRI contrast in the choroid plexus cells of rat brain in vivo over a period of 14 days. Ten microlitres of 2.5 x 10(10) PFU/ml nuclear-targeted LacZ-encoding Baavi with bUSPIO coating was injected into rat brain ventricles and visualized by MRI at 4.7 T. As baculoviruses exhibit restricted cell-type specificity in the rat brain, altered MRI contrast was detected in the choroid plexus of the injected ve…

BiodistributionPathologymedicine.medical_specialtyGenetic VectorsBiologyFerric CompoundsViral vectorLateral ventriclesTransduction GeneticIn vivoGeneticsMedical imagingmedicineAnimalsTissue DistributionMolecular Biologymedicine.diagnostic_testBrainColocalizationMagnetic resonance imagingGenetic Therapybeta-GalactosidaseMagnetic Resonance ImagingRatsNanoparticlesMolecular MedicineChoroid plexusBaculoviridaeBiomarkersGene Therapy
researchProduct

CMR 2005: 12.06: Ultra-small iron oxide nanoparticle (USPIO)-labeled baculoviruses as novel MRI agents for imaging viral vector biodistributionin vivo

2006

Biodistributionchemistry.chemical_compoundChemistryIn vivoBiophysicsIron oxideNanoparticleRadiology Nuclear Medicine and imagingVirologyViral vectorContrast Media & Molecular Imaging
researchProduct

Optimization of retroviral-mediated gene transfer to human NOD/SCID mouse repopulating cord blood cells through a systematic analysis of protocol var…

1999

Abstract Retroviral transduction of human hematopoietic stem cells is still limited by lack of information about conditions that will maximize stem cell self-renewal divisions in vitro. To address this, we first compared the kinetics of entry into division of single human CD34 + CD38 − cord blood (CB) cells exposed in vitro to three different flt3-ligand (FL)-containing cytokine combinations. Of the three combinations tested, FL + hyperinterleukin 6 (HIL-6) yielded the least clones and these developed at a slow rate. With either FL + Steel factor (SF) + HIL-6 + thrombopoietin (TPO) or FL + SF + interleukin 3 (IL-3) + IL-6 + granulocyte-colony-stimulating factor (G-CSF), >90% of the cells th…

Cancer ResearchGenetic VectorsCD34Antigens CD34Stem cell factorMice SCIDCD38BiologyImmunophenotypingViral vectorMiceNAD+ NucleosidaseAntigens CDMice Inbred NODTransduction GeneticGeneticsAnimalsHumansADP-ribosyl CyclaseMolecular BiologyInterleukin 3Membrane GlycoproteinsGene Transfer TechniquesInfant NewbornMembrane ProteinsCell BiologyHematologyFetal BloodADP-ribosyl Cyclase 1Antigens DifferentiationVirologyMolecular biologyHaematopoiesisRetroviridaeCord bloodStem cellCell DivisionExperimental Hematology
researchProduct

PO-298 MYC favours the onset of tumour initiating cells by inducing epigenetic reprogramming of mammary epithelial cells towards a stem cell-like sta…

2018

ABSTRACT Introduction Breast cancer consists of highly heterogenous tumours whose cell of origin resulted difficult to be defined. Recent findings highlighted the possibility that tumor-initiating cells (TICs) may arise from dedifferentiation of lineage-committed cells, by reactivation of multipotency in response to oncogenic insults. MYC is the most frequently amplified oncogene in breast cancer and the activation of MYC pathway has been associated with the basal-like subtype, which is characterised by poor survival and lack of a specific therapeutic strategy. Although MYC has been considered a driver oncogene in breast cancer, its mechanism of action in tumour initiation has been poorly a…

Cancer ResearchOncogeneSomatic cellCellBiologyViral vectorChromatinmedicine.anatomical_structureOncologyCancer researchmedicineStem cellReprogrammingTranscription factorESMO Open
researchProduct

AAV vector-mediated overexpression of CB1 cannabinoid receptor in pyramidal neurons of the hippocampus protects against seizure-induced excitoxicity.

2010

The CB1 cannabinoid receptor is the most abundant G-protein coupled receptor in the brain and a key regulator of neuronal excitability. There is strong evidence that CB1 receptor on glutamatergic hippocampal neurons is beneficial to alleviate epileptiform seizures in mouse and man. Therefore, we hypothesized that experimentally increased CB1 gene dosage in principal neurons would have therapeutic effects in kainic acid (KA)-induced hippocampal pathogenesis. Here, we show that virus-mediated conditional overexpression of CB1 receptor in pyramidal and mossy cells of the hippocampus is neuroprotective and moderates convulsions in the acute KA seizure model in mice. We introduce a recombinant a…

Central Nervous SystemCannabinoid receptormedicine.medical_treatmentHippocampuslcsh:MedicineHippocampal formationHippocampuschemistry.chemical_compoundMiceReceptor Cannabinoid CB1Neurobiology of Disease and RegenerationTransgeneslcsh:ScienceNeuronsRecombination GeneticMultidisciplinaryBehavior AnimalNeuromodulationmusculoskeletal neural and ocular physiologyfood and beveragesNeurochemistryGenomicsGene TherapyDependovirusEndocannabinoid systemCell biologyFunctional GenomicsNeurologyHomeostatic MechanismsMedicinelipids (amino acids peptides and proteins)Viral VectorsNeurochemicalsGenetic EngineeringResearch ArticleBiotechnologyKainic acidGenetic VectorsGreen Fluorescent ProteinsNeurophysiologyBiologyMicrobiologyVector BiologyGlutamatergicGenomic MedicineSeizuresmedicineGeneticsAnimalsBiologyEpilepsyIntegrasesDentate gyruslcsh:RMolecular biologyMice Inbred C57BLchemistryGene Expression Regulationnervous systemGenetics of DiseaseSynapseslcsh:QCannabinoidGene FunctionMolecular NeuroscienceAnimal GeneticsTransgenicsNeuroscienceEndocannabinoidsPLoS ONE
researchProduct

Generation of tumor-reactive CTL against the tumor-associated antigen HER2 using retrovirally transduced dendritic cells derived from CD34+ hemopoiet…

2000

Abstract Ag-specific CD8+ CTL are crucial for effective tumor rejection. Attempts to treat human malignancies by adoptive transfer of tumor-reactive CTL have been limited due to the difficulty of generating and expanding autologous CTL with defined Ag specificity. The current study examined whether human CTL can be generated against the tumor-associated Ag HER2 using autologous dendritic cells (DC) that had been genetically engineered to express HER2. DC progenitors were expanded by culturing CD34+ hemopoietic progenitor cells in the presence of the designer cytokine HyperIL-6. Proliferating precursor cells were infected by a retroviral vector encoding the HER2 Ag and further differentiated…

Cytotoxicity ImmunologicAdoptive cell transferReceptor ErbB-2T cellRecombinant Fusion ProteinsImmunologyAntigen-Presenting CellsImmunoglobulinschemical and pharmacologic phenomenaAntigens CD34BiologyMajor histocompatibility complexLymphocyte ActivationViral vectorCell LineAntigens CDTransduction GeneticMHC class IHLA-A2 AntigenmedicineTumor Cells CulturedImmunology and AllergyHumansProgenitor cellskin and connective tissue diseasesAntigen PresentationMembrane GlycoproteinsInterleukin-6Cell DifferentiationDendritic CellsReceptors InterleukinHematopoietic Stem CellsMolecular biologyReceptors Interleukin-6Peptide FragmentsCell biologyClone CellsCTL*medicine.anatomical_structureRetroviridaebiology.proteinCD8Cell DivisionT-Lymphocytes CytotoxicJournal of immunology (Baltimore, Md. : 1950)
researchProduct

Lentiviral-Mediated Gene Therapy in Fanconi Anemia-A Mice Reveals Long-Term Engraftment and Continuous Turnover of Corrected HSCs

2015

International audience; Fanconi anemia is a DNA repair-deficiency syndrome mainly characterized by cancer predisposition and bone marrow failure. Trying to restore the hematopoietic function in these patients, lentiviral vector-mediated gene therapy trials have recently been proposed. However, because no insertional oncogenesis studies have been conducted so far in DNA repair-deficiency syndromes such as Fanconi anemia, we have carried out a genome-wide screening of lentiviral insertion sites after the gene correction of Fanca-/- hematopoietic stem cells (HSCs), using LAM-PCR and 454-pyrosequencing. Our studies first demonstrated that transduction of Fanca-/- HSCs with a lentiviral vector d…

DNA RepairDNA repair[SDV]Life Sciences [q-bio]Genetic enhancementGenetic VectorsBiologymedicine.disease_causePolymerase Chain ReactionViral vectorCell LineMiceFanconi anemiaTransduction Genetichemic and lymphatic diseasesDrug DiscoveryGeneticsmedicineAnimalsMolecular BiologyGenetics (clinical)Mice KnockoutFanconi Anemia Complementation Group A ProteinLentivirusBone marrow failureGenetic Therapymedicine.diseaseHematopoietic Stem CellsFANCA3. Good health[SDV] Life Sciences [q-bio]Fanconi AnemiaCancer researchMolecular MedicineStem cellCarcinogenesis
researchProduct